We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M Turnover 44.83%
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
+30.01%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$3.1B
AUM Growth
+$358M
Cap. Flow
-$124M
Cap. Flow %
-4.01%
Top 10 Hldgs %
35.61%
Holding
108
New
34
Increased
17
Reduced
30
Closed
18
Avg Time Held Equity + Options
0.9 years
Top 10 Avg Time Held Equity + Options
0.2 years
Top 20 Avg Time Held Equity + Options
0.5 years
Avg Time Held Equity only
0.9 years
Top 10 Avg Time Held Equity only
0.2 years
Top 20 Avg Time Held Equity only
0.5 years

Top Buys

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$63.9M
2
MRK icon
Merck
MRK
+$61.9M
3
CI icon
Cigna
CI
+$60.7M
4
CGON icon
CG Oncology
CGON
+$59.4M
5
ISRG icon
Intuitive Surgical
ISRG
+$53.3M

Top Sells

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$81.9M
2
KRTX icon
Karuna Therapeutics, Inc. Common Stock
KRTX
+$65.2M
3
IMGN icon
Immunogen Inc
IMGN
+$54.2M
4
BHVN icon
Biohaven
BHVN
+$53.1M
5
ZTS icon
Zoetis
ZTS
+$47.4M

Sector Composition

Rank Sector Weight
1 Healthcare 90.71%
2 Miscellaneous 9.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ITCI icon
1
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$239M 7.72%
+600,000
New +$41.2M
2024 Q1
0 quarters
FUSN icon
2
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$139M 4.47%
6,500,328
– –
2023 Q1
4 quarters
BSX icon
3
Boston Scientific
BSX
$64B
$134M 4.32%
1,956,000
+66,000
+3% +$4.24M
2022 Q1
8 quarters
ARVN icon
4
Arvinas
ARVN
$468M
$123M 3.97%
2,985,190
+73
+0% +$3.19K
2020 Q2
15 quarters
ISRG icon
5
Intuitive Surgical
ISRG
$151B
$90.2M 2.91%
226,000
+141,000
+166% +$53.3M
2023 Q4
1 quarter
DNTH icon
6
Dianthus Therapeutics
DNTH
$4.17B
$81.5M 2.63%
2,717,554
+1,500,000
+123% +$32.6M
2023 Q3
2 quarters
ACHC icon
7
Acadia Healthcare
ACHC
$2.89B
$79.6M 2.57%
1,005,000
-151,692
-13% -$12.4M
2022 Q2
7 quarters
NBIX icon
8
Neurocrine Biosciences
NBIX
$13.9B
$74M 2.39%
536,500
-121,500
-18% -$16.6M
2020 Q4
13 quarters
NTRA icon
9
Natera
NTRA
$58.3B
$73.5M 2.37%
803,300
-306,700
-28% -$23.1M
2020 Q3
14 quarters
JAZZ icon
10
Jazz Pharmaceuticals
JAZZ
$13.9B
$70.3M 2.27%
584,000
+94,881
+19% +$11.6M
2022 Q2
7 quarters
AVTR icon
11
Avantor
AVTR
$10.9B
$68.9M 2.22%
2,695,000
+573,156
+27% +$13.6M
2023 Q4
1 quarter
CI icon
12
Cigna
CI
$79B
$67M 2.16%
+184,500
New +$60.7M
2024 Q1
0 quarters
MRK icon
13
Merck
MRK
$358B
$66.2M 2.14%
+502,000
New +$61.9M
2024 Q1
0 quarters
REGN icon
14
Regeneron Pharmaceuticals
REGN
$82B
$65.4M 2.11%
68,000
– –
2023 Q1
4 quarters
CGON icon
15
CG Oncology
CGON
$5.48B
$63.9M 2.06%
+1,454,765
New +$59.4M
2024 Q1
0 quarters
ILMN icon
16
Illumina
ILMN
$40.5B
$63.7M 2.05%
+477,095
New +$63.9M
2024 Q1
0 quarters
THC icon
17
Tenet Healthcare
THC
$22.2B
$63.2M 2.04%
601,000
-270,000
-31% -$24.3M
2022 Q4
5 quarters
ALGN icon
18
Align Technology
ALGN
$10.6B
$62M 2%
189,000
+33,200
+21% +$9.74M
2023 Q4
1 quarter
SNDX icon
19
Syndax Pharmaceuticals
SNDX
$1.22B
$57.4M 1.85%
2,412,500
-1,537,500
-39% -$34.3M
2020 Q2
15 quarters
LLY icon
20
Eli Lilly
LLY
$1.12T
$54.5M 1.76%
70,000
-15,000
-18% -$10.7M
2023 Q2
3 quarters
UTHR icon
21
United Therapeutics
UTHR
$23.2B
$49.8M 1.61%
217,000
-20,202
-9% -$4.56M
2023 Q4
1 quarter
ALPN icon
22
DELISTED
Alpine Immune Sciences Inc
ALPN
$46.6M 1.5%
+1,174,700
New +$34.7M
2024 Q1
0 quarters
RARE icon
23
Ultragenyx Pharmaceutical
RARE
$1.5B
$43.6M 1.41%
933,500
+89,000
+11% +$4.2M
2021 Q3
10 quarters
CVS icon
24
CVS Health
CVS
$118B
$43.5M 1.4%
545,000
-195,000
-26% -$14.9M
2023 Q4
1 quarter
SGRY icon
25
Surgery Partners
SGRY
$1.93B
$43.1M 1.39%
1,445,000
+279,068
+24% +$8.73M
2022 Q3
6 quarters
1
2 3 4 5

Similar funds

ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
CWM
Chemistry Wealth Management New York $625M AUM 19.32% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return
PWS
Proactive Wealth Strategies Marietta, Georgia $623M AUM 30.7% 1-Year Est. Return
LWP
LMG Wealth Partners Shreveport, Louisiana $626M AUM 36.27% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return

Avidity Partners Management's Q1 2024 Portfolio in Review

As of Q1 2024, Avidity Partners Management held 108 positions worth $3.1B, up 13% from $2.74B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Avidity Partners Management withdrew a net $124M in Q1 2024, closing 18 positions and reducing 30 holdings. Its most notable exit was Karuna Therapeutics, Inc. Common Stock, an estimated $65.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 95% a quarter earlier, followed by Miscellaneous.

Against the trend, Avidity Partners Management opened a new position in Illumina worth $63.7M.

  • Avidity Partners Management's largest Q1 2024 buy was Illumina: 477,095 shares worth $63.7M.
  • Avidity Partners Management added most to Intuitive Surgical in Q1 2024, an estimated $53.3M increase.
  • Avidity Partners Management's biggest Q1 2024 reduction was Thermo Fisher Scientific, cutting an estimated $81.9M.
  • Avidity Partners Management fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $65.2M.
  • Avidity Partners Management's ten largest holdings make up 36% of its $3.1B portfolio in Q1 2024.
  • Avidity Partners Management opened 34 new positions and closed 18 in Q1 2024.
  • Avidity Partners Management's portfolio value rose 13% quarter-over-quarter to $3.1B.

Based on Avidity Partners Management's 13F filing for Q1 2024, filed 15 May 2024.